Peptide questions · Melanotan I
Melanotan I side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for Melanotan I are nausea, facial flushing and darkening of moles and freckles, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: The approved implant's label (Scenesse) warns that afamelanotide darkens the skin generally and darkens existing moles and freckles, and recommends a full-body skin exam twice a year to watch existing and new pigmented spots; serious allergic reactions, including anaphylaxis, have been reported since approval.
What is commonly reported with Melanotan I
- Nausea
- Facial flushing
- Darkening of moles and freckles
- Injection site reaction
- Fatigue
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 7) |
|---|---|
| Nausea | 2: PT-141, Melanotan II |
| Facial flushing | 1: Melanotan II |
| Darkening of moles and freckles | None: listed for Melanotan I alone |
| Injection site reaction | 1: Kisspeptin-10 |
| Fatigue | 2: Melanotan II, HCG |

Which Melanotan I side effects the sexual health group shares
Across the 8 sexual health compounds in the library, the effects listed most often are fatigue (3 of 8), headache (3 of 8), nausea (3 of 8) and facial flushing (2 of 8). Melanotan I shares 4 of its 5 listed effects with at least one other sexual health compound; darkening of moles and freckles is listed for Melanotan I alone.
What the Melanotan I safety notes say
The library’s safety note
The approved implant's label (Scenesse) warns that afamelanotide darkens the skin generally and darkens existing moles and freckles, and recommends a full-body skin exam twice a year to watch existing and new pigmented spots; serious allergic reactions, including anaphylaxis, have been reported since approval. In its EPP trials the common side effects were implant-site reactions (21% vs 10% on placebo), nausea (19% vs 14%) and fatigue (6% vs 3%); in the early tanning trials they were mild nausea and brief facial flushing. Research-grade "Melanotan 1" sold online is unregulated, so its purity and dose aren't controlled. New or changing moles are worth a dermatologist's look; discuss the rest with your clinician.
The library’s interaction note
No drug interaction studies were done for afamelanotide (Scenesse label). Running it with Melanotan II or PT-141 doubles up on melanocortin receptors, and no study has tested those combinations. Discuss all your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the Melanotan I reports come from
The library rates the evidence on Melanotan I as established: clinical trials or FDA-approved use exist.
Of the library’s 6 research notes on Melanotan I, 6 rest on clinical data.
Our 10 study pages on Melanotan I: 4 observational studies, 3 clinical trials and 3 randomized trials.
So Melanotan I has controlled trials in people to set its listed effects against.
What our Melanotan I study pages report on safety
Melanotan I: well tolerated in 6 acute stroke patients
Clinical trial, human, 2023: One patient died of a second stroke on day 9, tied to a known complete blockage of the internal carotid artery and judged unrelated to the drug, and no other local or major whole-body side effects were seen. This is a first small safety check of Melanotan I (afamelanotide) in stroke patients, not evidence that it improves stroke recovery.
Melanotan I: more pain-free sun time in protoporphyria trials
Randomized trial, human, 2015: Side effects were mostly mild, and the serious ones were not judged to be caused by the drug. In this rare light-sensitivity disease, afamelanotide implants were linked to more pain-free time in the sun and better quality of life than placebo, with mostly mild side effects.
Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168
Randomized trial, human, 2015: The gain showed up in skin types IV to VI but not in skin type III; both groups had skin redness, and the combined group also had nausea and minor infections.
Melanotan I: full uptake under the skin, tanning in 3 men
Randomized trial, human, 1997: The forehead, arms, and neck tanned clearly after vein or under-the-skin dosing; tanning peaked 1 week after dosing and was still there 3 weeks after the ten doses ended, while side effects were minimal, mainly occasional stomach upset and facial flushing.
Questions people ask
What are the side effects of Melanotan I?
The side effects most commonly reported for Melanotan I are nausea, facial flushing and darkening of moles and freckles, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Do Melanotan I’s side effects come from human studies?
The library rates the evidence on Melanotan I as established, and the library’s evidence on it includes controlled trials in people.
Which Melanotan I side effects are its own?
Among the sexual health compounds, the library lists darkening of moles and freckles for Melanotan I alone.
Does Melanotan I interact with other medicines?
The library’s interaction note on Melanotan I begins: No drug interaction studies were done for afamelanotide (Scenesse label).